# Forepont Capital Partners

> Forepont Capital Partners is a VC fund backing Medical and Biotechnology. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 15
- Last investment: Oct 2025
- Lead investor: 47%
- Fund size: $130M
- Last fund: Apr 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/forepontgrouplp/
- Website: http://forepont.com/

Forepont Capital Partners is a VC fund in New York focused on Medical and Biotechnology. Forepont Capital Partners provides permanent capital to invest in the asset manager and strengthen this partnership. It was founded in 2014 and is based in New York. Forepont's mission is to provide scientific, technological, financial, and operational support to biotech, medtech, and e-health start-ups in the United States and Europe.Forepont boosts its performance by leveraging its talent, expertise, partners, and global ecosystem.

## Contacts

5 contacts available for Forepont Capital Partners. Shizune tracks 3 team members at Forepont Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/forepont-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 33% |
| Biotechnology | 4 | 27% |
| Medical Device | 4 | 27% |
| Health Care | 3 | 20% |
| Pharmaceutical | 3 | 20% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 40% |
| Series B | 3 | 20% |
| Series C | 2 | 13% |
| Seed | 1 | 7% |
| Venture - Series Unknown | 1 | 7% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 4 | 27% |
| United States | 4 | 27% |
| Australia | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bruce Greenberg | CFO | 0 | https://shizune.co/investors/profile/bruce-greenberg-9ad1 |
| Eric M. Attias | Managing Partner & Co-Founder | 1 | https://shizune.co/investors/profile/eric-m-attias |
| Julien Tizot | General Partner | 0 | https://shizune.co/investors/profile/julien-tizot |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Exeliom | Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $3.3M | Series A | Oct 21, 2025 |  |
| Okeiro | Okeiro offers an AI platform for chronic disease and transplant care, enabling early detection, monitoring, and treatment. | $11.3M | Series A | Apr 10, 2025 |  |
| AlterDiag | AlterDiag mission is to develop and commercialize innovative lateral flow immunochromatographic tests using technologies like single-chain variable fragment antibodies. | $2.1M | Seed | Jan 29, 2025 |  |
| Precision Neuroscience | Precision Neuroscience is a neural platform for next-generation brain-computer interface technology. The company's goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. Its brain–computer interface is designed to be minimally invasive, safely removable, and capable ofprocessing large amounts of data.The company was founded in 2021 and is based in New York. | $102M | Series C | Nov 06, 2024 |  |
| GPN Vaccines | GPN Vaccines are a type of vaccine that is used to prevent the spread developing a vaccine against streptococcus pneumoniae. | $12M | Series B | Jun 06, 2024 |  |
| basecamp vascular | basecamp vascular is a medtech company that offers a Robotic solution for endovascular navigation. | $6.5M | Series A | Dec 13, 2023 |  |
| GPN Vaccines | GPN Vaccines are a type of vaccine that is used to prevent the spread developing a vaccine against streptococcus pneumoniae. | $6.3M | Series A | Jan 31, 2023 |  |
| Precision Neuroscience | Precision Neuroscience is a neural platform for next-generation brain-computer interface technology. The company's goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. Its brain–computer interface is designed to be minimally invasive, safely removable, and capable ofprocessing large amounts of data.The company was founded in 2021 and is based in New York. | $41M | Series B | Jan 25, 2023 |  |
| Synchron | Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic. | $75M | Series C | Dec 16, 2022 |  |
| Synchron | Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic. | $75M | Series C | Dec 15, 2022 |  |

10 of 15 investments shown.

## Co-investors
- [B Capital](https://shizune.co/investors/profile/b-capital-group) — VC Fund, 3 deals together
- [ID8 Investments](https://shizune.co/investors/profile/id8-investments) — VC Fund, 3 deals together
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 3 deals together
- [METIS innovative](https://shizune.co/investors/profile/metis-innovative) — VC Fund, 3 deals together
- [Neurotechnology Investors](https://shizune.co/investors/profile/neurotechnology-investors-nti) — VC Fund, 3 deals together
- [Steadview Capital](https://shizune.co/investors/profile/steadview-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Forepont Capital Partners invest in?

Forepont Capital Partners invests primarily in Medical, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Forepont Capital Partners?

Public channels for Forepont Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Forepont Capital Partners?

The team at Forepont Capital Partners includes Bruce Greenberg (CFO), Eric M. Attias (Managing Partner & Co-Founder) and Julien Tizot (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co